UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102, UGN-103 which is in phase 3 of clinical trial for intravesical solution, and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Period	Debt/Equity
2017-12-31	0.10
2018-12-31	0.15
2019-12-31	0.12
2020-12-31	0.27
2021-12-31	13.23
2022-12-31	-2.52
2023-12-31	-3.73
2024-12-31	-33.46

	A	B	C	D
1	Symbol	Price	Change	Volume
2	URGN	$18.82	+0.00%	0.38M
3
4
5

UroGen Pharma Ltd. (URGN) Debt to Equity Ratio

Debt to Equity Ratio Data

Get UroGen Pharma Ltd. Data in Excel

More URGN Financial Data